Psyched Wellness Ltd (QB) (PSYCF) Quote

Sloooow. Won’t move for another year

Zzzz back to no trades. Hate being locked in this.

I see these guys make coconut water. Not sure if they can add it directly to that brand or will they make a new product? They need to do that. Add 2mL in each bottle or can. Sell with their distribution chain.

Put AME in their coconut water.

Need product lists. They plan on just pushing the tincture? THC infused beverages are booming. They’re missing the boat. That is if they can get into a beverage. Or a vape. I don’t see news coming on product for another 6-12 months.

Pay Attention to the players. They are not going to risk their integrity for some penny stock scam. They have a lifelong family history of success!!

People don't realize how Big this announcement Today actually is. :)

They are planning to disrupt the industry, it's going to be monumental. $$$$

Volume sucks though. Maybe one day market makers will let go of their short position. From .55c to .02 is dreadful.

Regardless I’m happy we got something. I want the vape pen. That’s the game changer if they can figure that out.

Yes. My avg is double that. Thought .12 was bottom. My big mistake. Don’t see this hitting over .10 till 2025 maybe.

How do you get $30-$50 when it’s at .03c? Do you know how market caps work? Do the math. This isn’t huge news. It’s all structured to dilute at .07c and .10c at anytime if and when the price hits.

It looks like the warrants are priced at around 7.3 cents (which is about a 90% increase from the current share price).

PSYCF is a start up company. Don't you know how that works?

So with today's news are you going to stop crying?

It's Huge news!

$30 -$50 price target = PSYCF



.

More warrants but it’s better than nothing.

Psyched Wellness and Gotham Green Partners to Close Final Tranche of US$2.5M for a Total of US$7.5M Raised and Partner with Strategic Advisors to Build Consumer Packaged Goods Derived from AME-1

Toronto, Ontario--(Newsfile Corp. - April 19, 2024) - Psyched Wellness Ltd. (CSE: PSYC) (OTCQB: PSYCF) (FSE: 5U9) (the "Company" or "Psyched Wellness"), a life sciences company focused on the production and distribution of health and wellness products derived from the Amanita Muscaria mushroom, is pleased to announce that it has entered into a master services agreement (the "Master Services Agreement") with Zerkalo, LLC, a New York partnership ("Zerkalo"), pursuant to which the Company has engaged Zerkalo to develop product development, marketing, distribution and supply chain set up for a product derived from AME-1 (the "Product"), in accordance with the terms and conditions of the Master Services Agreement and accompanying statement of work (the "SOW" and together with the Master Services Agreement, the "Transaction Documents") for a period of the greater of: (x) thirty months and (y) the time required to complete any services still outstanding pursuant to the Transaction Documents at the end of the thirty month period.

"Closing the last tranche of the financing with Gotham Green Partners and securing Zerkalo's investment and partnership to build out our consumer packaged goods ("CPG") brand representing a transformational moment for Psyched Wellness and its shareholders," said Jeffrey Stevens, Chief Executive Officer of the Company. "As the founders of Harmless Harvest, Justin and Douglas have an incredible track record of building brands and creating value for its investors, and we are thrilled to have them lead this next chapter for Psyched Wellness," added Mr. Stevens.

"Douglas and Justin's shared alignment with our Company's vision and enthusiasm for the potential of AME-1 as a leading-edge CPG product is invaluable. With their wealth of experience and creativity, we are thrilled to collaborate in bringing Amanita products to the mass market," said David Shisel, Chief Operating Officer of the Company.

"Over the past years we have been on the lookout for a truly disruptive ingredient that can demonstrate value in tangibly improving the quality of modern life. While a broad variety of novel fungi and plants have made their way into the food and beverage aisles in the past few years, few have delivered on the promise and surging demand for wellness you can actually feel. Amanita gives us a whole new product design vocabulary that shows great promise and mass appeal. We're thrilled to join these pioneers and establish a truly needed product for the health conscious consumer," said Justin Guilbert.

"Fifteen years ago, Justin and I nurtured the dream of an integrated supply chain that values conservation, sustainability, and the complexity of biotopes. With Psyched Wellness's Amanita we finally have a non timber forest product to champion and scale to meaningful environmental impact. Better for you should be better for the planet. This opportunity is one of the rare models that can deliver a blueprint for better food systems," added Douglas Riboud.

Messrs. Guilbert and Riboud have been collaborating on developing and delivering radically innovative consumer products for the past fifteen years. As founders, they are best known for creating 'Harmless Harvest' - the plant-based juggernaut famed for its iconic coconut water. They have been involved in numerous projects, from beauty to seafood, with a core mission to successfully establish purpose or "conscious" capitalism as the next iteration for a modern construct of consumerism.

Transaction Details

Pursuant to the terms and conditions of the Transaction Documents, the Company will allocate a budget $2,250,000 in cash towards Zerkalo, payable in ten quarterly installments of $225,000 to achieve the milestones outlined in the SOW and issue to Zerkalo an aggregate of 35,066,632 advisory warrants (each, an "Advisory Warrant") within ten days of signing the Transaction Documents. These milestones include, but are not limited to, the creation of a brand/brand identity, product development/formulation, packaging conception and execution, development of marketing material, sales support and merchandising asset development, review and selection of copacker partners and strategy, oversight of pilot and production runs, go-to-market/sales-and-distribution (channel selection, positioning analysis, soft launch with core audience, channel support execution, field sales support strategy and activation, promotional strategy, negotiation and execution), and project management and finance.

Each Advisory Warrant will entitle Zerkalo to acquire one common share in the capital of the Company (each, a "Common Share") at a price of C$0.10 per Common Share (the "Exercise Price") at any time for a period of sixty months from the date of issuance, subject to certain vesting conditions. Subject to the Transaction Documents not being terminated prior to the applicable vesting date, 23,377,755 Advisory Warrants shall vest in quarterly installments over the span of ten quarters and the remaining 11,688,877 Advisory Warrants shall vest only upon the completion of the Product's launch.

The Advisory Warrants and the Common Shares underlying their exercise will be subject to: (i) a four (4) month and one (1) day hold period from the date of issuance and (ii) applicable legends as required pursuant to the U.S. Securities Act.

Private Placement Update

Further to the Company's press releases dated May 30, 2023 (the "May 30 Release") and June 12, 2023 (the "June 12 Release"), September 1, 2023 (the "September 1 Release"), September 5, 2023 and January 17, 2024, notwithstanding the fact that Gotham's (as defined in the June 12 Release) exclusivity elapsed on November 8, 2023, the Company and Gotham are continuing to work towards closing Tranche 2B (as defined in the September 1 Release). Capitalized terms not otherwise defined herein have the meanings attributed to them in the May 30 Release.

Pursuant to the terms and conditions of the Amended and Restated Investor Rights Agreement (as defined in the September 1 Release), upon satisfaction and/or waiver of the Tranche 2B Closing Conditions (as defined in the September 1 Release) and receipt of a closing notice, the parties will close a final tranche of the Offering for gross proceeds of US$2,500,000. Each Unit will be sold at a price of C$0.07 per Unit and will consist of one (1) Common Share and one (1) Warrant. Each Warrant will entitle the holder thereof to acquire one (1) Additional Share at a price of C$0.10 per Additional Share at any time for a period of sixty (60) months from the date of issuance, exercisable on a cashless basis, subject to acceleration and compliance with the policies of the CSE, as further outlined in the May 30 Release.

All securities issuable under Tranche 2B will be subject to: (i) a four (4) month and one (1) day hold period from the date of issuance and (ii) applicable legends as required pursuant to the U.S. Securities Act. The Company intends to use the net proceeds from the Offering for working capital and general corporate purposes.

Upon closing of Tranche 2B, and during the remainder of the Nomination Period (as defined in the September 1 Release), Gotham shall be entitled to designate the Third Nominee (as defined in the September 1 Release), replacing one existing member of the Board (who shall not be the First Nominee or Second Nominee (each as defined in the September 1 Release)), bringing the total Board representation of Gotham to three (3) members, and maintaining the board size at seven (7), provided that no more than three (3) Board members, at any time, will be employees or partners of the Investors (as defined in the June 12 Release) or their affiliates.

Gotham has no obligation to acquire any Units under Tranche 2B. The Units issuable in connection with Tranche 2B shall be issued to the Investors within five (5) business days following the satisfaction and/or waiver of the Tranche 2B Closing Conditions, subject to the terms and conditions of the Amended and Restated Investor Rights Agreement.

The Investors in Tranche 2B will enter into lock-up agreements with the Company to refrain from selling any Units acquired in Tranche 2B (and any securities underlying such Units acquired in Tranche 2B) for a period of twelve (12) months following closing of Tranche 2B.

https://www.newsfilecorp.com/release/206158

This company is over. Ame1 is as useless as tits on a bull. Big pharma doesn’t need a 5000 yr old mushroom in the way. He’s the only company in the world with this compound and still nobody wants it.

Point is, ceo pushed his FOMO in qtr 3 last year for eoy and beginning of 2024 full well knowing sales were low and no product launches. Dont know why GG would invest in this if they don’t bring out new products. The addition to her on the board is meaningless. They have no desire to propel this business.

She knows what GGP wants her to know. :)

Imagine being in a stock that has no volume. They will shut this company down. Its done.

That chic is 22 yrs old. She knows nothing.

Hopefully nobody will replace him. They can’t find key acccounts anyways. It’s a dead tincture for the price. Own it, nobody ready and willing for a fungus.

Jeff will continue to get millions of shares just so long the share price is low. Executing warrants.

$700k salaries in 2023. For what? $300k in sales? This is a shell company and they’re treating it like one. They don’t care about investors. Simple.

Matt Singh is gone. Did you not read the PR?

I did read the Financials and I don't recall see $500k salary but I do agree the salaries are high Especially for Shisel.

Jeff owns Millions of shares. Matt was supposed to get back to me about a couple things but he dropped the ball. So probably not a good fit for that position. Let's see who will replace him. :)

Well the "chic" on the board is from GGP. the "cfo" did Not leave. Stay tuned to find out what Japan means.

Who recalls the ceo saying late 2023 early 2024 we would see fomo? What a douche

Ain’t nobody buying gay ass mushroom sleep juice. Take the loss if you can get out. This will never go back to .10c. They stopped all research. Can’t blame them when they dilute, execute warrants, pay CEO $500k annually with sales dropping from 320k in 2022 to 220k in 2023. They won’t pay to keep this listed much longer. CE soon. Dump before its to late because it will go under a penny within a month.

That is why the cfo left. He wants nothing to do with this company after financials came out. Literally 99% of otc is scam.

You read those financials? Warrants executed, dilluted, salaries are so high for ceo. He’s paying himself 500k and sales are 300k. He’s a criminal. Everyone bailed that believed in the mushroom. Another shell otc scam!

This is going pink soon and under .0001
They are so fkt. Taking a loss even further.

Sales dropped significantly from 2022 to 2023. They made more in 2022 than 2023. How is that possible?

Unreal.

Sales $320k
Operating expenses -3.5M

Yea, they’re done.

I’ll send this piece of sheet to .009 with my sells.

1/4th out. Sell it all. Going out of business.

I bought the hype bs on the vape patent. What a crock I got into. You can’t smoke a mushroom. Sold 9,000. Just want out

I don’t know why you sink money in this. There’s no buyers it’s a swamp you buy and you can’t get your money out. They drained it all to shorts and they’re happy to keep it going lower on no volume. The ceo opened this up well over 50m value and now it’s at 6m and will probably go lower as AME-1 isn’t as popular as they hoped. Especially given the price and uncertainty of this mushroom making one sick. I just want out, avg is .12c

Pivot? I see true mushroom stocks rising but this one clearly isn’t a part of that clan. It’s not a psychedelic so why would it catch any bids. CFO left, the character you claimed would clear a path in sales and marketing. He failed and ran. Didn’t even mention why he left. This company is dead.

I bought more PSYCF last week. The pivot is in full effect.

If you ever searched for Amanita Muscaria OR Muscimol....

Did you notice the difference in the Google results from 3 - 4 years ago to Today?

Ever hear of ... "laying the ground work"?

And tomorrow markets are closed.

CEO told me news qtr 1. Well tomorrow is last day. He’s either waiting or full of it. The fact his Red Bull guru left and he’s without a CFO is alarming in itself.

There was a mention in the past about Amanita Muscaria gummies. This could have a wider appeal than the sublingual tincture and perhaps avoid the bad taste. Are these gummies being sold by PSYCF? Thanks.

CEO said news this qtr he has three days left. If nothing this company is truly a pos. They show no signs of wanting to sell product. Marketing is crap. Maybe GG is doing a job. I should have bought 1m shares of rolls Royce.

Clearly headed under a Penny soon. Just a matter of time. .009 next quarter

What a pos. CEO doesn’t say a word.

we are not in financial trouble, to the contrary, we are one of the few micro caps in our sector that is cashed up and positioned for growth. We are excited about 2024 and have some exciting product development in the pipeline that we aim to announce this quarter. Trading near our cash position, the only public company with a legal for human consumption product derived from Amanita Muscaria and selling in the USA. I
appreciate you taking the time to connect and hope this has provided some good insights for you.
Jeff

Can’t even sell bc there’s no volume. Total disaster bs scam stock. All of the employees have left. I’m certain they stopped producing Calm. It’s no longer in Central Market.

Psycf was a shell bought by the ceo. How otc usually work. They buy a previous ticker in the red. When this opened up a few years ago millions of shares were trading for a few weeks then the inevitable downward spiral to here with no trades. It’s done imho

That is interesting what you say Copilotdog. Mel Brooks made a movie called “The Producers” where they plotted to have the play so ridiculous that it would fail.

Is there any evidence of sizable shorting by a coordinated group of insiders with PSYCF. Is it illegal for management to collude with schemers to tank a company to give a profit to short position holders?

Would the SEC want to hear about this sort of thing?

Central Market pulled Calm off the shelves. Was no longer there yesterday. I asked about it and they said they returned the case because it wasn’t selling. Go figure. I honestly believe they only forged a few runs and have purposely failed as every snake investor either cashed out at open a few years ago or shorted it all the way to zero.